Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

Ipilimumab (IPI) 10 mg/kg with sargramostim (GM-CSF; GM) improved overall survival (OS) and safety of patients with advanced melanoma over IPI in a randomized phase II trial. The FDA-approved dose of IPI 3 mg/kg has not been assessed with GM (IPI-GM). Consecutive patients treated with IPI-GM at a si...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Immunol Res
Huvudupphovsmän: Luke, Jason J., Donahue, Hilary, Nishino, Mizuki, Giobbie-Hurder, Anita, Davis, Meredith, Bailey, Nancy, Ott, Patrick A., Hodi, F. Stephen
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561189/
https://ncbi.nlm.nih.gov/pubmed/25943535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0066
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk